Spots Global Cancer Trial Database for Malignant Pediatric Pelvic Tumors: A Retrospective Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Malignant Pediatric Pelvic Tumors: A Retrospective Study

Official Title: Malignant Pediatric Pelvi-abdominal Tumors: A Retrospective Study

Study ID: NCT02557256

Conditions

Abdominal Neoplasms

Pelvic Neoplasms

Interventions

Study Description

Brief Summary: The aim of the study is to retrospectively review data about malignancies that arise primarily in the pelvis and/or in the pelvic organs, in pediatric cancer patients \& categorize the spectrum of these malignancies according to experience at South Egypt Cancer Institute which is the largest referral site in Upper Egypt.

Detailed Description: Background: The newborn and infant pelvis is not fully developed and the bladder, uterus, and ovaries are to a large degree intra-abdominal. The pelvis of the infant and child has different anatomic relationships than the adolescent or adult pelvis. Neoplasms of the pediatric pelvis constitute a unique group requiring highly specialized management in a setting staffed by pediatric surgical and radiation oncologists. The most common neoplasms are rhabdomyosarcomas of the bladder, prostate, and vagina; sacrococcygeal teratoma; and the germ cell tumors, including teratomas, endodermal sinus tumors, and the choriocarcinomas. Rapidly improving chemotherapy for all of these lesions has resulted in a changed role for the surgeon. Patients \& Methods: A hospital-based study, involving Pediatric cancer patients, those have been diagnosed with malignant tumors that primarily arising in the pelvis and/or arising from the pelvic organs, and may have an intra-abdominal extension, in the period from 2001 January till 2015 December, and received treatment at the pediatric oncology department, their medical reports will be retrospectively reviewed for data collection. Spectrum of these malignancies will be categorized and recorded as specific disease entities, based on morphology \& the primary site of occurrence, their relative incidence will be calculated, and the treatment outcomes will be verified.